Tanzania
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.54 (3.43 - 3.66) | 2019 | Modelled | IHME |
| 3.63 (3.53 - 3.74) | 2018 | Modelled | IHME |
| 3.77 (3.66 - 3.89) | 2017 | Modelled | IHME |
| 3.99 (3.87 - 4.11) | 2016 | Modelled | IHME |
| 4.22 (4.10 - 4.37) | 2015 | Modelled | IHME |
| 4.39 (4.26 - 4.54) | 2014 | Modelled | IHME |
| 4.52 (4.40 - 4.68) | 2013 | Modelled | IHME |
| 4.65 (4.52 - 4.81) | 2012 | Modelled | IHME |
| 4.78 (4.64 - 4.95) | 2011 | Modelled | IHME |
| 4.92 (4.77 - 5.11) | 2010 | Modelled | IHME |
| 5.09 (4.93 - 5.27) | 2009 | Modelled | IHME |
| 5.27 (5.11 - 5.45) | 2008 | Modelled | IHME |
| 5.45 (5.28 - 5.65) | 2007 | Modelled | IHME |
| 5.63 (5.45 - 5.86) | 2006 | Modelled | IHME |
| 5.8 (5.60 - 6.05) | 2005 | Modelled | IHME |
| 5.97 (5.76 - 6.23) | 2004 | Modelled | IHME |
| 6.15 (5.92 - 6.42) | 2003 | Modelled | IHME |
| 6.32 (6.08 - 6.60) | 2002 | Modelled | IHME |
| 6.47 (6.22 - 6.77) | 2001 | Modelled | IHME |
| 6.57 (6.30 - 6.91) | 2000 | Modelled | IHME |
| 6.64 (6.37 - 6.98) | 1999 | Modelled | IHME |
| 6.69 (6.43 - 7.04) | 1998 | Modelled | IHME |
| 6.74 (6.47 - 7.09) | 1997 | Modelled | IHME |
| 6.78 (6.50 - 7.15) | 1996 | Modelled | IHME |
| 6.83 (6.53 - 7.22) | 1995 | Modelled | IHME |
| 6.88 (6.59 - 7.25) | 1994 | Modelled | IHME |
| 6.93 (6.66 - 7.31) | 1993 | Modelled | IHME |
| 6.98 (6.71 - 7.36) | 1992 | Modelled | IHME |
| 7.03 (6.74 - 7.42) | 1991 | Modelled | IHME |
| 7.08 (6.78 - 7.47) | 1990 | Modelled | IHME |
| 3.5 (2.10 - 5) | 2017 | Survey/reported | Tanzania HIV Impact Survey (THIS) 2016-2017, 2018 |
| 4.03 (3.06 - 5.16) | 2015 | Modelled | WHO |
| 7.17 (6.59 - 7.79) | 2013 | Modelled | Schweitzer et al, 2015 |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.38 (0.31 - 0.45) | 2019 | Modelled | IHME |
| 0.41 (0.34 - 0.50) | 2018 | Modelled | IHME |
| 0.44 (0.36 - 0.55) | 2017 | Modelled | IHME |
| 0.47 (0.39 - 0.56) | 2016 | Modelled | IHME |
| 0.49 (0.40 - 0.59) | 2015 | Modelled | IHME |
| 0.5 (0.42 - 0.60) | 2014 | Modelled | IHME |
| 0.51 (0.43 - 0.60) | 2013 | Modelled | IHME |
| 0.52 (0.43 - 0.62) | 2012 | Modelled | IHME |
| 0.53 (0.44 - 0.64) | 2011 | Modelled | IHME |
| 0.55 (0.45 - 0.66) | 2010 | Modelled | IHME |
| 0.59 (0.49 - 0.71) | 2009 | Modelled | IHME |
| 0.67 (0.55 - 0.80) | 2008 | Modelled | IHME |
| 0.77 (0.64 - 0.92) | 2007 | Modelled | IHME |
| 0.9 (0.76 - 1.07) | 2006 | Modelled | IHME |
| 1.06 (0.88 - 1.27) | 2005 | Modelled | IHME |
| 1.43 (1.20 - 1.71) | 2004 | Modelled | IHME |
| 2.06 (1.73 - 2.47) | 2003 | Modelled | IHME |
| 2.77 (2.33 - 3.33) | 2002 | Modelled | IHME |
| 3.36 (2.81 - 4.09) | 2001 | Modelled | IHME |
| 3.66 (3.02 - 4.50) | 2000 | Modelled | IHME |
| 3.73 (3.08 - 4.62) | 1999 | Modelled | IHME |
| 3.78 (3.11 - 4.75) | 1998 | Modelled | IHME |
| 3.82 (3.11 - 4.80) | 1997 | Modelled | IHME |
| 3.85 (3.11 - 4.85) | 1996 | Modelled | IHME |
| 3.88 (3.10 - 4.92) | 1995 | Modelled | IHME |
| 3.91 (3.15 - 4.91) | 1994 | Modelled | IHME |
| 3.95 (3.20 - 4.92) | 1993 | Modelled | IHME |
| 3.98 (3.24 - 4.92) | 1992 | Modelled | IHME |
| 4.01 (3.29 - 4.92) | 1991 | Modelled | IHME |
| 4.03 (3.31 - 4.99) | 1990 | Modelled | IHME |
| 1.69 (1.08 - 2.54) | 2015 | Modelled | WHO |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 2.82 (1.81 - 4.06) | 2019 | Modelled | IHME |
| 3.02 (1.94 - 4.31) | 2018 | Modelled | IHME |
| 3.1 (2.02 - 4.42) | 2017 | Modelled | IHME |
| 3.01 (1.96 - 4.29) | 2016 | Modelled | IHME |
| 2.97 (1.94 - 4.21) | 2015 | Modelled | IHME |
| 3.15 (2.08 - 4.41) | 2014 | Modelled | IHME |
| 3.51 (2.35 - 4.81) | 2013 | Modelled | IHME |
| 3.92 (2.70 - 5.33) | 2012 | Modelled | IHME |
| 4.3 (3.02 - 5.86) | 2011 | Modelled | IHME |
| 4.59 (3.27 - 6.11) | 2010 | Modelled | IHME |
| 4.73 (3.41 - 6.24) | 2009 | Modelled | IHME |
| 4.84 (3.54 - 6.37) | 2008 | Modelled | IHME |
| 4.92 (3.56 - 6.53) | 2007 | Modelled | IHME |
| 4.97 (3.65 - 6.53) | 2006 | Modelled | IHME |
| 5.04 (3.69 - 6.64) | 2005 | Modelled | IHME |
| 5.07 (3.71 - 6.59) | 2004 | Modelled | IHME |
| 5.09 (3.75 - 6.74) | 2003 | Modelled | IHME |
| 5.11 (3.75 - 6.76) | 2002 | Modelled | IHME |
| 5.22 (3.84 - 6.93) | 2001 | Modelled | IHME |
| 5.17 (3.73 - 6.87) | 2000 | Modelled | IHME |
| 5.06 (3.63 - 6.69) | 1999 | Modelled | IHME |
| 4.86 (3.52 - 6.49) | 1998 | Modelled | IHME |
| 4.9 (3.55 - 6.62) | 1997 | Modelled | IHME |
| 4.93 (3.57 - 6.70) | 1996 | Modelled | IHME |
| 4.99 (3.59 - 6.79) | 1995 | Modelled | IHME |
| 5.06 (3.65 - 6.90) | 1994 | Modelled | IHME |
| 5.12 (3.68 - 7.01) | 1993 | Modelled | IHME |
| 5.15 (3.67 - 7.01) | 1992 | Modelled | IHME |
| 5.21 (3.71 - 7.01) | 1991 | Modelled | IHME |
| 5.27 (3.75 - 7.15) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 1,602 (1,027 - 2,303) | 2019 | Modelled | IHME |
| 1,668 (1,072 - 2,384) | 2018 | Modelled | IHME |
| 1,671 (1,088 - 2,383) | 2017 | Modelled | IHME |
| 1,580 (1,028 - 2,249) | 2016 | Modelled | IHME |
| 1,520 (990 - 2,152) | 2015 | Modelled | IHME |
| 1,568 (1,034 - 2,196) | 2014 | Modelled | IHME |
| 1,702 (1,140 - 2,331) | 2013 | Modelled | IHME |
| 1,848 (1,272 - 2,511) | 2012 | Modelled | IHME |
| 1,973 (1,388 - 2,691) | 2011 | Modelled | IHME |
| 2,050 (1,462 - 2,729) | 2010 | Modelled | IHME |
| 2,058 (1,485 - 2,715) | 2009 | Modelled | IHME |
| 2,051 (1,503 - 2,700) | 2008 | Modelled | IHME |
| 2,031 (1,472 - 2,696) | 2007 | Modelled | IHME |
| 2,001 (1,470 - 2,628) | 2006 | Modelled | IHME |
| 1,977 (1,448 - 2,604) | 2005 | Modelled | IHME |
| 1,935 (1,416 - 2,517) | 2004 | Modelled | IHME |
| 1,896 (1,395 - 2,510) | 2003 | Modelled | IHME |
| 1,852 (1,359 - 2,450) | 2002 | Modelled | IHME |
| 1,840 (1,353 - 2,445) | 2001 | Modelled | IHME |
| 1,775 (1,281 - 2,360) | 2000 | Modelled | IHME |
| 1,693 (1,214 - 2,236) | 1999 | Modelled | IHME |
| 1,582 (1,144 - 2,110) | 1998 | Modelled | IHME |
| 1,552 (1,123 - 2,096) | 1997 | Modelled | IHME |
| 1,518 (1,099 - 2,062) | 1996 | Modelled | IHME |
| 1,493 (1,074 - 2,032) | 1995 | Modelled | IHME |
| 1,472 (1,062 - 2,008) | 1994 | Modelled | IHME |
| 1,446 (1,041 - 1,981) | 1993 | Modelled | IHME |
| 1,415 (1,007 - 1,924) | 1992 | Modelled | IHME |
| 1,390 (991 - 1,869) | 1991 | Modelled | IHME |
| 1,365 (972 - 1,852) | 1990 | Modelled | IHME |
| 2,750 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 25 (19 - 33) | 2019 | Modelled | IHME |
| 25 (19 - 33) | 2018 | Modelled | IHME |
| 25 (19 - 33) | 2017 | Modelled | IHME |
| 25 (19 - 33) | 2016 | Modelled | IHME |
| 25 (19 - 32) | 2015 | Modelled | IHME |
| 25 (19 - 33) | 2014 | Modelled | IHME |
| 25 (19 - 32) | 2013 | Modelled | IHME |
| 25 (19 - 33) | 2012 | Modelled | IHME |
| 26 (20 - 33) | 2011 | Modelled | IHME |
| 26 (20 - 34) | 2010 | Modelled | IHME |
| 26 (20 - 34) | 2009 | Modelled | IHME |
| 26 (20 - 34) | 2008 | Modelled | IHME |
| 26 (19 - 33) | 2007 | Modelled | IHME |
| 26 (19 - 33) | 2006 | Modelled | IHME |
| 26 (19 - 34) | 2005 | Modelled | IHME |
| 26 (20 - 34) | 2004 | Modelled | IHME |
| 26 (20 - 34) | 2003 | Modelled | IHME |
| 26 (20 - 34) | 2002 | Modelled | IHME |
| 26 (20 - 34) | 2001 | Modelled | IHME |
| 26 (20 - 34) | 2000 | Modelled | IHME |
| 27 (20 - 34) | 1999 | Modelled | IHME |
| 27 (21 - 35) | 1998 | Modelled | IHME |
| 27 (21 - 35) | 1997 | Modelled | IHME |
| 27 (21 - 35) | 1996 | Modelled | IHME |
| 27 (21 - 35) | 1995 | Modelled | IHME |
| 27 (20 - 35) | 1994 | Modelled | IHME |
| 27 (20 - 35) | 1993 | Modelled | IHME |
| 26 (20 - 35) | 1992 | Modelled | IHME |
| 26 (20 - 34) | 1991 | Modelled | IHME |
| 26 (20 - 34) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 98 | 2018 | Survey/reported | WHO/UNICEF |
| 97 | 2017 | Survey/reported | WHO/UNICEF |
| 97 | 2016 | Survey/reported | WHO/UNICEF |
| 98 | 2015 | Survey/reported | WHO/UNICEF |
| 97 | 2014 | Survey/reported | WHO/UNICEF |
| 91 | 2013 | Survey/reported | WHO/UNICEF |
| 92 | 2012 | Survey/reported | WHO/UNICEF |
| 90 | 2011 | Survey/reported | WHO/UNICEF |
| 91 | 2010 | Survey/reported | WHO/UNICEF |
| 85 | 2009 | Survey/reported | WHO/UNICEF |
| 86 | 2008 | Survey/reported | WHO/UNICEF |
| 83 | 2007 | Survey/reported | WHO/UNICEF |
| 90 | 2006 | Survey/reported | WHO/UNICEF |
| 90 | 2005 | Survey/reported | WHO/UNICEF |
| 95 | 2004 | Survey/reported | WHO/UNICEF |
| 95 | 2003 | Survey/reported | WHO/UNICEF |
| 89 | 2002 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 2 (1 - 3) | 2016 | Survey/reported | Larney S et al, 2017 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.48 (1.17 - 1.85) | 2019 | Modelled | IHME |
| 1.47 (1.17 - 1.84) | 2018 | Modelled | IHME |
| 1.47 (1.17 - 1.83) | 2017 | Modelled | IHME |
| 1.46 (1.18 - 1.82) | 2016 | Modelled | IHME |
| 1.45 (1.17 - 1.81) | 2015 | Modelled | IHME |
| 1.45 (1.18 - 1.81) | 2014 | Modelled | IHME |
| 1.45 (1.17 - 1.81) | 2013 | Modelled | IHME |
| 1.45 (1.17 - 1.82) | 2012 | Modelled | IHME |
| 1.45 (1.16 - 1.82) | 2011 | Modelled | IHME |
| 1.45 (1.16 - 1.82) | 2010 | Modelled | IHME |
| 1.45 (1.16 - 1.82) | 2009 | Modelled | IHME |
| 1.46 (1.17 - 1.82) | 2008 | Modelled | IHME |
| 1.47 (1.17 - 1.83) | 2007 | Modelled | IHME |
| 1.48 (1.18 - 1.84) | 2006 | Modelled | IHME |
| 1.48 (1.18 - 1.84) | 2005 | Modelled | IHME |
| 1.48 (1.19 - 1.84) | 2004 | Modelled | IHME |
| 1.48 (1.19 - 1.84) | 2003 | Modelled | IHME |
| 1.48 (1.20 - 1.83) | 2002 | Modelled | IHME |
| 1.48 (1.20 - 1.83) | 2001 | Modelled | IHME |
| 1.48 (1.20 - 1.84) | 2000 | Modelled | IHME |
| 1.48 (1.20 - 1.84) | 1999 | Modelled | IHME |
| 1.48 (1.19 - 1.84) | 1998 | Modelled | IHME |
| 1.47 (1.18 - 1.83) | 1997 | Modelled | IHME |
| 1.47 (1.18 - 1.84) | 1996 | Modelled | IHME |
| 1.47 (1.18 - 1.85) | 1995 | Modelled | IHME |
| 1.47 (1.18 - 1.84) | 1994 | Modelled | IHME |
| 1.47 (1.19 - 1.84) | 1993 | Modelled | IHME |
| 1.48 (1.19 - 1.84) | 1992 | Modelled | IHME |
| 1.48 (1.19 - 1.86) | 1991 | Modelled | IHME |
| 1.49 (1.20 - 1.87) | 1990 | Modelled | IHME |
Showing out of
Show more
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1 | 2017 | Survey/reported | Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), 2018 |
| 2.7 (0.20 - 7.80) | 2014 | Modelled | Riou et al, 2015 |
Showing out of
Show more
People living with HIV (PLHIV)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.5 | 2017 | Survey/reported | Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), 2018 |
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 27.7 (22.40 - 33.50) | 2011 | Survey/reported | Bowring AL et al, 2013 |
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 5.63 (3.78 - 7.84) | 2019 | Modelled | IHME |
| 5.6 (3.77 - 7.73) | 2018 | Modelled | IHME |
| 5.6 (3.82 - 7.61) | 2017 | Modelled | IHME |
| 5.57 (3.80 - 7.65) | 2016 | Modelled | IHME |
| 5.65 (3.85 - 7.70) | 2015 | Modelled | IHME |
| 5.74 (4 - 7.71) | 2014 | Modelled | IHME |
| 5.8 (4.15 - 7.78) | 2013 | Modelled | IHME |
| 5.81 (4.23 - 7.73) | 2012 | Modelled | IHME |
| 5.87 (4.34 - 7.65) | 2011 | Modelled | IHME |
| 6.07 (4.51 - 7.89) | 2010 | Modelled | IHME |
| 6.26 (4.70 - 8.11) | 2009 | Modelled | IHME |
| 6.44 (4.85 - 8.30) | 2008 | Modelled | IHME |
| 6.58 (4.93 - 8.45) | 2007 | Modelled | IHME |
| 6.68 (5.01 - 8.60) | 2006 | Modelled | IHME |
| 6.78 (5.04 - 8.73) | 2005 | Modelled | IHME |
| 6.8 (5.07 - 8.70) | 2004 | Modelled | IHME |
| 6.8 (5.08 - 8.78) | 2003 | Modelled | IHME |
| 6.78 (5.15 - 8.71) | 2002 | Modelled | IHME |
| 6.86 (5.25 - 8.77) | 2001 | Modelled | IHME |
| 6.75 (5.17 - 8.64) | 2000 | Modelled | IHME |
| 6.57 (5.05 - 8.47) | 1999 | Modelled | IHME |
| 6.26 (4.80 - 8.05) | 1998 | Modelled | IHME |
| 6.34 (4.76 - 8.13) | 1997 | Modelled | IHME |
| 6.39 (4.83 - 8.19) | 1996 | Modelled | IHME |
| 6.47 (4.85 - 8.36) | 1995 | Modelled | IHME |
| 6.57 (4.87 - 8.52) | 1994 | Modelled | IHME |
| 6.64 (4.96 - 8.62) | 1993 | Modelled | IHME |
| 6.7 (5.01 - 8.70) | 1992 | Modelled | IHME |
| 6.77 (5.08 - 8.76) | 1991 | Modelled | IHME |
| 6.85 (5.15 - 8.91) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 3,196 (2,145 - 4,449) | 2019 | Modelled | IHME |
| 3,093 (2,083 - 4,273) | 2018 | Modelled | IHME |
| 3,016 (2,055 - 4,099) | 2017 | Modelled | IHME |
| 2,925 (1,991 - 4,011) | 2016 | Modelled | IHME |
| 2,889 (1,969 - 3,933) | 2015 | Modelled | IHME |
| 2,855 (1,987 - 3,838) | 2014 | Modelled | IHME |
| 2,807 (2,007 - 3,768) | 2013 | Modelled | IHME |
| 2,740 (1,995 - 3,645) | 2012 | Modelled | IHME |
| 2,695 (1,990 - 3,510) | 2011 | Modelled | IHME |
| 2,712 (2,017 - 3,526) | 2010 | Modelled | IHME |
| 2,726 (2,044 - 3,530) | 2009 | Modelled | IHME |
| 2,730 (2,059 - 3,518) | 2008 | Modelled | IHME |
| 2,716 (2,038 - 3,491) | 2007 | Modelled | IHME |
| 2,688 (2,014 - 3,461) | 2006 | Modelled | IHME |
| 2,658 (1,974 - 3,423) | 2005 | Modelled | IHME |
| 2,598 (1,937 - 3,323) | 2004 | Modelled | IHME |
| 2,530 (1,890 - 3,265) | 2003 | Modelled | IHME |
| 2,456 (1,868 - 3,157) | 2002 | Modelled | IHME |
| 2,422 (1,852 - 3,093) | 2001 | Modelled | IHME |
| 2,319 (1,775 - 2,968) | 2000 | Modelled | IHME |
| 2,196 (1,689 - 2,830) | 1999 | Modelled | IHME |
| 2,038 (1,562 - 2,620) | 1998 | Modelled | IHME |
| 2,006 (1,507 - 2,571) | 1997 | Modelled | IHME |
| 1,967 (1,485 - 2,521) | 1996 | Modelled | IHME |
| 1,936 (1,452 - 2,501) | 1995 | Modelled | IHME |
| 1,910 (1,418 - 2,479) | 1994 | Modelled | IHME |
| 1,878 (1,402 - 2,436) | 1993 | Modelled | IHME |
| 1,839 (1,376 - 2,390) | 1992 | Modelled | IHME |
| 1,806 (1,354 - 2,336) | 1991 | Modelled | IHME |
| 1,775 (1,333 - 2,309) | 1990 | Modelled | IHME |
| 1,749 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 20 (14 - 27) | 2019 | Modelled | IHME |
| 20 (14 - 27) | 2018 | Modelled | IHME |
| 20 (14 - 27) | 2017 | Modelled | IHME |
| 19 (13 - 26) | 2016 | Modelled | IHME |
| 19 (13 - 26) | 2015 | Modelled | IHME |
| 19 (13 - 26) | 2014 | Modelled | IHME |
| 19 (13 - 26) | 2013 | Modelled | IHME |
| 19 (13 - 25) | 2012 | Modelled | IHME |
| 19 (13 - 25) | 2011 | Modelled | IHME |
| 19 (13 - 25) | 2010 | Modelled | IHME |
| 19 (13 - 25) | 2009 | Modelled | IHME |
| 19 (13 - 25) | 2008 | Modelled | IHME |
| 19 (13 - 25) | 2007 | Modelled | IHME |
| 19 (13 - 25) | 2006 | Modelled | IHME |
| 19 (13 - 25) | 2005 | Modelled | IHME |
| 19 (13 - 25) | 2004 | Modelled | IHME |
| 19 (13 - 25) | 2003 | Modelled | IHME |
| 19 (13 - 25) | 2002 | Modelled | IHME |
| 18 (13 - 25) | 2001 | Modelled | IHME |
| 18 (13 - 25) | 2000 | Modelled | IHME |
| 18 (13 - 25) | 1999 | Modelled | IHME |
| 18 (13 - 25) | 1998 | Modelled | IHME |
| 18 (13 - 25) | 1997 | Modelled | IHME |
| 18 (13 - 25) | 1996 | Modelled | IHME |
| 18 (13 - 25) | 1995 | Modelled | IHME |
| 18 (13 - 25) | 1994 | Modelled | IHME |
| 18 (13 - 24) | 1993 | Modelled | IHME |
| 18 (13 - 24) | 1992 | Modelled | IHME |
| 18 (13 - 24) | 1991 | Modelled | IHME |
| 18 (13 - 24) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 300 (1 - 3) | 2016 | Survey/reported | Larney S et al, 2017 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
Overview
HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030
Prevalence (national)
Modelled
HBV (HBsAg+)
3.54
(%)
2019
(3.43 - 3.66(%))
IHME
HCV (RNA/cAg+)
1.48
(%)
2019
(1.17 - 1.85(%))
IHME
Survey/surveillance
HBV (HBsAg+)
3.5
(%)
2017
(2.1 - 5(%))
Tanzania HIV Impact Survey (THIS) 2016-2017, 2018
HCV (anti-HCV)
1
(%)
2017
Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), 2018
Hepatitis related deaths (national)
Modelled
HBV
1,602
2019
(1,027 - 2,303)
IHME
Survey/surveillance
No data available
HBV chart
Modelled
HCV
3,196
2019
(2,145 - 4,449)
IHME
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.38
(%)
2019, latest modelled
(0.31 - 0.45(%))
IHME
Prevalence PWID
HCV
27.70
(%)
2011, survey/surveillance
(22.40 - 33.50(%))
Bowring AL et al, 2013
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
HCV
2
2016
(1 - 3)
Larney S et al, 2017
Eligible for HBV generic medicines
Eligible for HCV generic medicines
